Skip to main content
Top
Published in: Clinical Oral Investigations 8/2015

01-11-2015 | Original Article

Cost-effective analysis of topical chlorhexidine in hematologic patients at risk for oral mucositis

Authors: Sharon Elad, Todd Thierer

Published in: Clinical Oral Investigations | Issue 8/2015

Login to get access

Abstract

Objective

The aim of this study was to explore whether management of mucositis with Chlorhexidine (CHX) mouthwash could be a cost-effective method to decrease the risk of mortality and economic burden in hemato-oncologic or hematopoietic stem cell transplantation (HSCT) patients.

Methods

A cost-effectiveness analysis model of prophylactic CHX mouthwash use versus no-CHX mouthwash use for the prevention of oral mucositis was developed for patients undergoing cytotoxic therapy or HSCT. The outcome variable was survival. The primary variables were CHX mouthwash use, probability of mucositis, probability of increased hospital stay, and length of hospital stay. Probability and cost data were obtained from the literature.

Results

Our analysis selected CHX mouthwash use during anticancer treatment as the preferred strategy for the base-case analysis as compared to no CHX mouthwash (marginal value 0.032). There was a $14,391 cost difference per patient between the two strategies.

Conclusion

The results of this study suggest that CHX mouthwash use during anticancer treatment results in an increased survival and decreased cost for the population studied. Using our base-case data, an additional 32 of every 1,000 hemato-oncologic or HSCT patients will survive when employing the preferred strategy of prophylactic CHX mouthwash.

Clinical relevance

CHX mouthwash should be offered for hematologic patients undergoing HSCT or administered with chemotherapy.
Literature
4.
go back to reference Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19(8):2201–2205PubMed Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19(8):2201–2205PubMed
5.
go back to reference Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, McCabe MG, Meyer S, Khalid T (2011) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev (4):CD000978. doi:10.1002/14651858.CD000978.pub5 Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, McCabe MG, Meyer S, Khalid T (2011) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev (4):CD000978. doi:10.​1002/​14651858.​CD000978.​pub5
6.
go back to reference Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831. doi:10.1002/cncr.22484 CrossRefPubMed Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820–831. doi:10.​1002/​cncr.​22484 CrossRefPubMed
7.
go back to reference McGuire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J, Elad S, Gibson F, Oberle-Edwards LK, Bowen J, Lalla RV (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21(11):3165–3177. doi:10.1007/s00520-013-1942-0 CrossRefPubMed McGuire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J, Elad S, Gibson F, Oberle-Edwards LK, Bowen J, Lalla RV (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21(11):3165–3177. doi:10.​1007/​s00520-013-1942-0 CrossRefPubMed
8.
go back to reference Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S (2008) Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 112(7):1600–1606. doi:10.1002/cncr.23328 CrossRefPubMed Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S (2008) Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 112(7):1600–1606. doi:10.​1002/​cncr.​23328 CrossRefPubMed
9.
go back to reference Soares AF, Aquino AR, Carvalho CH, Nonaka CF, Almeida D, Pinto LP (2011) Frequency of oral mucositis and microbiological analysis in children with acute lymphoblastic leukemia treated with 0.12% chlorhexidine gluconate. Braz Dent J 22(4):312–316CrossRefPubMed Soares AF, Aquino AR, Carvalho CH, Nonaka CF, Almeida D, Pinto LP (2011) Frequency of oral mucositis and microbiological analysis in children with acute lymphoblastic leukemia treated with 0.12% chlorhexidine gluconate. Braz Dent J 22(4):312–316CrossRefPubMed
10.
go back to reference Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA (1997) Primer on medical decision analysis: Part 1—getting started. Med Decis Mak 17(2):123–125CrossRef Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA (1997) Primer on medical decision analysis: Part 1—getting started. Med Decis Mak 17(2):123–125CrossRef
11.
go back to reference Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D (1997) Primer on medical decision analysis: Part 2—building a tree. Med Decis Mak 17(2):126–135CrossRef Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D (1997) Primer on medical decision analysis: Part 2—building a tree. Med Decis Mak 17(2):126–135CrossRef
12.
go back to reference Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS (1997) Primer on medical decision analysis: Part 3—estimating probabilities and utilities. Med Decis Mak 17(2):136–141CrossRef Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS (1997) Primer on medical decision analysis: Part 3—estimating probabilities and utilities. Med Decis Mak 17(2):136–141CrossRef
13.
go back to reference Richardson WS, Detsky AS (1995) Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working Group. JAMA 273(20):1610–1613CrossRefPubMed Richardson WS, Detsky AS (1995) Users' guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? Evidence Based Medicine Working Group. JAMA 273(20):1610–1613CrossRefPubMed
14.
go back to reference Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S (2007) Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 15(5):491–496. doi:10.1007/s00520-006-0176-9 CrossRefPubMed Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S (2007) Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer 15(5):491–496. doi:10.​1007/​s00520-006-0176-9 CrossRefPubMed
15.
go back to reference Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M (1994) Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 30B(2):93–97CrossRefPubMed Borowski B, Benhamou E, Pico JL, Laplanche A, Margainaud JP, Hayat M (1994) Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 30B(2):93–97CrossRefPubMed
16.
go back to reference Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT (1987) Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 114(4):461–467CrossRefPubMed Ferretti GA, Ash RC, Brown AT, Largent BM, Kaplan A, Lillich TT (1987) Chlorhexidine for prophylaxis against oral infections and associated complications in patients receiving bone marrow transplants. J Am Dent Assoc 114(4):461–467CrossRefPubMed
17.
go back to reference Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT (1988) Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 3(5):483–493PubMed Ferretti GA, Ash RC, Brown AT, Parr MD, Romond EH, Lillich TT (1988) Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 3(5):483–493PubMed
18.
go back to reference McGaw WT, Belch A (1985) Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen. Oral Surg Oral Med Oral Pathol 60(3):275–280CrossRefPubMed McGaw WT, Belch A (1985) Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen. Oral Surg Oral Med Oral Pathol 60(3):275–280CrossRefPubMed
19.
go back to reference Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A (2003) Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. J Hosp Infect 53(4):283–291CrossRefPubMed Pitten FA, Kiefer T, Buth C, Doelken G, Kramer A (2003) Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. J Hosp Infect 53(4):283–291CrossRefPubMed
21.
go back to reference Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98(7):1531–1539. doi:10.1002/cncr.11671 CrossRefPubMed Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98(7):1531–1539. doi:10.​1002/​cncr.​11671 CrossRefPubMed
22.
go back to reference Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590–2598. doi:10.1056/NEJMoa040125 CrossRefPubMed Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590–2598. doi:10.​1056/​NEJMoa040125 CrossRefPubMed
23.
go back to reference Barasch A, Elad S, Altman A, Damato K, Epstein J (2006) Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer 14(6):528–532. doi:10.1007/s00520-006-0066-1 CrossRefPubMed Barasch A, Elad S, Altman A, Damato K, Epstein J (2006) Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis. Support Care Cancer 14(6):528–532. doi:10.​1007/​s00520-006-0066-1 CrossRefPubMed
24.
go back to reference Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG (2006) Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 85(8):690–700CrossRefPubMed Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL, de Vries EG (2006) Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses. J Dent Res 85(8):690–700CrossRefPubMed
25.
go back to reference Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104(2):579–585. doi:10.1182/blood-2004-01-0338 2004-01-0338 CrossRefPubMed Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104(2):579–585. doi:10.​1182/​blood-2004-01-0338 2004-01-0338 CrossRefPubMed
26.
go back to reference de Kok IM, Polder JJ, Habbema JD, Berkers LM, Meerding WJ, Rebolj M, van Ballegooijen M (2009) The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br J Cancer 100(8):1240–1244. doi:10.1038/sj.bjc.6605018 PubMedCentralCrossRefPubMed de Kok IM, Polder JJ, Habbema JD, Berkers LM, Meerding WJ, Rebolj M, van Ballegooijen M (2009) The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening. Br J Cancer 100(8):1240–1244. doi:10.​1038/​sj.​bjc.​6605018 PubMedCentralCrossRefPubMed
27.
go back to reference Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461. doi:10.1002/cncr.28592 PubMedCentralCrossRefPubMed Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461. doi:10.​1002/​cncr.​28592 PubMedCentralCrossRefPubMed
Metadata
Title
Cost-effective analysis of topical chlorhexidine in hematologic patients at risk for oral mucositis
Authors
Sharon Elad
Todd Thierer
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 8/2015
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-015-1438-z

Other articles of this Issue 8/2015

Clinical Oral Investigations 8/2015 Go to the issue